Scinai Immunotherapeutics (SCNI) Q2 2026 earnings summary

Executive summary

• Achieved $3.1 million in committed customer orders as of August 16, 2026, with $2.1 million invoiced.

• Expanded a key U.S. customer engagement into a broader clinical manufacturing and CMC program, receiving $650 thousand in cash payments and advances.

• Focused on integrating and expanding CDMO operations, particularly following the acquisition of Yavne and Recipharm Israel.

• Priorities for the remainder of 2026 include executing customer programs, increasing facility utilization, and advancing therapeutic programs.

Financial highlights

• Revenues rose to $949 thousand for H1 2026, up from $773 thousand year-over-year, mainly due to the Yavne acquisition.

• Cost of revenues increased to $3.3 million from $2.0 million, reflecting higher operating costs post-acquisition.

• Gross loss widened to $2.4 million from $1.3 million year-over-year.

• Operating loss was $4.6 million, compared to $3.8 million in H1 2025.

• Net income reached $1.6 million, reversing a $4.1 million net loss in H1 2025, driven by a $6.4 million bargain purchase gain from the Recipharm Israel acquisition.

• Cash, cash equivalents, and restricted cash totaled $2.9 million as of June 30, 2026.

Outlook and guidance

• Targeting approximately $5 million in CDMO revenues for 2026.

• Emphasis on commercial execution, pipeline conversion, and facility utilization in H2 2026.

• Ongoing negotiations for a definitive agreement with a major U.S. customer for expanded clinical manufacturing.